Replies to post #87864 on Amarantus Bioscience Holdings Inc (AMBS)

[barcode27]

Thanks... I was worried for a second before I realized that the assignee was UMass which has ties to Amarantus. If I'm reading the patent app correctly, it would seem that many of the claims go on to examine the use of MANF for treatment of beta-cell disorders (and not just the analysis of biomarkers in diagnostic tests). Very exciting!

[seebisquick]

Also, from the Mid-Year shareholder's letter:
"The most significant developments have occurred in our Massachusetts' subsidiary Amarantus-MA, which has adopted an increased focused on identifying potential orphan-drug applications for MANF under our Center of Excellence in Apoptosis Research ("CEAR") grant. Our scientific team there has made great strides in testing for the applicability of MANF in a variety of orphan indications and we expect to update shareholders with a pipeline of such indications in the coming months, as well as information on the first such indication in the coming weeks The overall development timeline for MANF in these orphan indications is expected to be dramatically reduced compared to the Parkinson's indication."

Could be related.